Acute Ischemic StrokeMETAPROFIL 1NCT07624396
Association Between Circulating BDNF Levels and Cardioembolic Strokes in Patients Treated for Ischemic Stroke
An observational study of Acute Ischemic Stroke, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
Trial summary
Atrial fibrillation (AF) is associated with serious complications, including embolic strokes, heart failure, and mortality. Disruption of normal blood flow in the atrium, particularly in the context of an endocardium predisposed to thrombosis, increases the risk of thrombus formation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Ischemic Stroke
- What is being tested?
- Circulating BDNF levels measured via blood sample
- How many people
- 150 participants
- Where
- 1 siteFrance
- Study dates
- 23 Sep 2026to Sep 2031
- How long will I take part?
- 36 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: A patient diagnosed with acute ischemic stroke, confirmed by brain imaging (CT or MRI).
Who may be able to join
- Individuals who provided informed consent
- Diagnosis of acute ischemic stroke confirmed by brain imaging (CT or MRI)
- Patient admitted to the USINV of the Department of General, Vascular, and Degenerative Neurology at the Dijon Bourgogne University Hospital during the inclusion period
- Underwent a combined cardiac and brain CT scan within 24 hours of admission for stroke
Who cannot join
- A person subject to a legal protective measure (guardianship, conservatorship)
- A person subject to a judicial safeguard measure
- A pregnant woman, a woman who has recently given birth, or a breastfeeding woman
- An adult who is legally incapacitated or unable to give consent,
- A minor
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Chu Dijon Bourgogne
Dijon
Yannick BEJOT, Pr, 03.80.29.37.53, yannick.bejot@chu-dijon.fr
About this study
Atrial fibrillation (AF) is associated with serious complications, including embolic strokes, heart failure, and mortality. Disruption of normal blood flow in the atrium, particularly in the context of an endocardium predisposed to thrombosis, increases the risk of thrombus formation. Once dislodged from the atrial cavity and traveling to the cerebral arteries, these thrombi can cause a cardioembolic stroke. The main risk factors for atrial cardiomyopathy (ACM) and AF are metabolic syndrome and aging.
ACM is a condition that is difficult to diagnose because it is not clearly defined, except through histological analysis. Guided by the results of our experimental approaches, the investigators aim to address this challenge by examining ACM through the lens of one of its complications: cardioembolic stroke. BDNF (Brain-Derived Neurotrophic Factor) is a neurotrophic factor involved in inflammatory and metabolic processes that may play a key role in the development of these complications.
This study explores the association between circulating levels of BDNF and the morphological and metabolic characteristics of ACM, as assessed by cardiac and brain imaging studies
- Conditions
- Acute Ischemic Stroke
- Being tested
- Circulating BDNF levels measured via blood sample
- Medical subject headings
- Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Circulating BDNF levels measured via blood sampleBiological
Diagnosis of cardioembolic stroke according to the TOAST13 classification, adjudicated with a blinded review of biomarker data by the treating of a neurologist upon the patient' s hospital discharge
| Study group | Role | What they receive |
|---|---|---|
| Patient who has suffered an acute ischemic stroke | Patient diagnosed with acute ischemic stroke based on brain imaging Receives: Biological: Circulating BDNF levels measured via blood sample |
What is being measured
The primary outcome is the main question the study is designed to answer.
Diagnosis of cardioembolic stroke according to the TOAST classification, adjudicated with a blinded review of biomarker data by the treating of a neurologist upon the patient' s hospital discharge.
Measured: At hospital discharge (approximately 5 to 10 day after admission)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2026
- Study start23 Sep 2026
- Primary completionSep 2031 (estimated)
- Study completionSep 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Ischemic StrokeStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire DijonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
- Target duration
- 36 Months
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire Dijon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07624396
- Sponsor's protocol ID
- GUENANCIA ANR 2024
- Acronym
- METAPROFIL 1
- Status last verified
- Sep 2026
- First submitted
- 17 Apr 2026
- Last updated
- 25 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association Between Circulating BDNF Levels and Cardioembolic Strokes in Patients Treated for Ischemic Stroke
- ClinicalTrials.gov ID
- NCT07624396
- Acronym / sponsor ID
- METAPROFIL 1 / GUENANCIA ANR 2024
- Conditions
- Acute Ischemic Stroke
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire DijonUniversity, hospital or other
- Study start
- 23 Sep 2026 (actual)
- Primary completion
- Sep 2031 (estimated)
- Study completion
- Sep 2031 (estimated)
- First posted
- 3 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Atrial fibrillation (AF) is associated with serious complications, including embolic strokes, heart failure, and mortality. Disruption of normal blood flow in the atrium, particularly in the context of an endocardium predisposed to thrombosis, increases the risk of thrombus formation. Once dislodged from the atrial cavity and traveling to the cerebral arteries, these thrombi can cause a cardioembolic stroke. The main risk factors for atrial cardiomyopathy (ACM) and AF are metabolic syndrome and aging.
ACM is a condition that is difficult to diagnose because it is not clearly defined, except through histological analysis. Guided by the results of our experimental approaches, the investigators aim to address this challenge by examining ACM through the lens of one of its complications: cardioembolic stroke. BDNF (Brain-Derived Neurotrophic Factor) is a neurotrophic factor involved in inflammatory and metabolic processes that may play a key role in the development of these complications.
This study explores the association between circulating levels of BDNF and the morphological and metabolic characteristics of ACM, as assessed by cardiac and brain imaging studies
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 36 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patient who has suffered an acute ischemic stroke | – | Biological: Circulating BDNF levels measured via blood samplePatient diagnosed with acute ischemic stroke based on brain imaging |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- A patient diagnosed with acute ischemic stroke, confirmed by brain imaging (CT or MRI).
Key inclusion criteria (4 listed)
- Individuals who provided informed consent
- Diagnosis of acute ischemic stroke confirmed by brain imaging (CT or MRI)
- Patient admitted to the USINV of the Department of General, Vascular, and Degenerative Neurology at the Dijon Bourgogne University Hospital during the inclusion period
- Underwent a combined cardiac and brain CT scan within 24 hours of admission for stroke
Key exclusion criteria (5 listed)
- A person subject to a legal protective measure (guardianship, conservatorship)
- A person subject to a judicial safeguard measure
- A pregnant woman, a woman who has recently given birth, or a breastfeeding woman
- An adult who is legally incapacitated or unable to give consent,
- A minor
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Circulating BDNF levels measured via blood sampleDiagnosis of cardioembolic stroke according to the TOAST13 classification, adjudicated with a blinded review of biomarker data by the treating of a neurologist upon the patient' s hospital discharge | Biological | Patient who has suffered an acute ischemic stroke |
Primary outcome
Diagnosis of cardioembolic stroke according to the TOAST classification, adjudicated with a blinded review of biomarker data by the treating of a neurologist upon the patient' s hospital discharge.
Time frame: At hospital discharge (approximately 5 to 10 day after admission)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2026.
Related trials for Acute Ischemic Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
RecruitingObservational study
Continuous Dual Aspiration Technique With Zoom System for Stroke
Ischemic Stroke, Acute Stroke
Not yet recruitingPhase 2/3
A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
Acute Ischemic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Ischemic Stroke, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Charles GUENANCIA, Pr (03.80.29.56.23, charles.guenancia@chu-dijon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Diagnosis of cardioembolic stroke according to the TOAST classification, adjudicated with a blinded review of biomarker data by the treating of a neurologist upon the patient' s hospital discharge. (time frame: At hospital discharge (approximately 5 to 10 day after admission)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026.